Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.

COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.

Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.

Inclusion Criteria:

COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.

Exclusion Criteria:

• Participants in other clinical trials
• patients with malignant tumors
• pregnant and lactating women
• co-infection with other infectious viruses or bacteria
• History of several allergies
• Patients with history of pulmonary embolism
• any liver or kidney diseases
• HIV positive patients
• Considered by researchers to be not suitable to participate in this clinical trial
• Chronic heart failure with ejection fraction less than 30%.